Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dabigatran is an oral anticoagulant used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), including after hip replacement surgery. Dabigatran acts as a direct thrombin inhibitor by reversibly binding to the active site of thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting clot formation[1][4][5][6][8]. Pitavastatin is an oral lipid-lowering agent used together with diet, weight loss, and exercise to reduce levels of low-density lipoprotein (LDL) cholesterol and other fatty substances in the blood. It belongs to the statin class (HMG-CoA reductase inhibitors) and works by inhibiting HMG-CoA reductase, a key enzyme involved in cholesterol synthesis[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dabigatran + pitavastatin.